Juno Therapeutics Inc (JUNO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Juno Therapeutics Inc (JUNO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH504874D
  • |
  • Pages: 77
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Juno Therapeutics Inc (Juno) is a clinical stage biotechnology company that develops immunotherapy platforms for the treatment of cancer. The company is formulating cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to identify and kill cancer cells. Its CD19 CAR and WT-1 TCR clinical programs include numerous product candidates in clinical development for several hematologic malignancies in adults and children. Juno invests in continued technology improvements and CAR and TCR product candidates targeting multiple cancer types. The company works in collaboration with various cancer centers to advance the development of immunotherapies. Juno is headquartered in Seattle, Washington, the US.

Juno Therapeutics Inc (JUNO)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 13

Venture Financing 13

Juno Therapeutics Raises USD134 Million in Series B Financing 13

Juno Therapeutics Raises US$31 Million In Extended Series A Financing 13

Juno Therapeutics Raises US$145 Million In Series A Financing 14

AbVitro Raises US$0.75 Million In Venture Financing 16

AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 16

X-BODY Raises Additional US$0.6 Million In Venture Financing 17

Partnerships 17

Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 17

Juno Therapeutics Forms Joint Venture with WuXi AppTec 18

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 19

Celgene Exercises Option Agreement with Juno Therapeutics 20

Juno Therapeutics Enters into Research Agreement with Editas Medicine 21

MedImmune Enters into Agreement with Juno Therapeutics 22

Juno Therapeutics Enters into Research Agreement with FHCRC 22

X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 23

X-BODY Enters Into Research Agreement With Tanabe Research Labs 24

Mercator Therapeutics Enters Into Co-Development Agreement With X-BODY BioSciences 25

Licensing Agreements 26

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 26

Celgene Enters into Licensing Agreement with Juno Therapeutics 27

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 28

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 29

Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 30

Vernalis Enters into Licensing Agreement with RedoxTherapies 31

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 32

Juno Therapeutics Enters into Licensing Agreement with FHCRC 33

Equity Offering 34

Juno Therapeutics Raises USD304 Million in IPO 34

Asset Transactions 35

Roche Acquires PETE Technology from AbVitro 35

Acquisition 36

Juno Therapeutics Acquires RedoxTherapies 36

Juno Therapeutics Acquires AbVitro 37

Juno Therapeutics Acquires X-BODY 38

AstraZeneca May Acquire Juno Therapeutics 39

Juno Therapeutics Acquires Remaining 95% Stake in Stage Cell Therapeutics 39

Juno Therapeutics Acquires ZetaRx BioSciences 40

Juno Therapeutics Inc-Key Competitors 42

Key Employees 43

Locations And Subsidiaries 44

Head Office 44

Other Locations & Subsidiaries 44

Recent Developments 45

Financial Announcements 45

Mar 01, 2017: Juno Therapeutics Reports Fourth Quarter and 2016 Financial Results 45

Nov 09, 2016: Juno Therapeutics Reports Third Quarter 2016 Financial Results 49

Aug 04, 2016: Juno Therapeutics Reports Second Quarter 2016 Financial Results 51

May 09, 2016: Juno Therapeutics Reports First Quarter 2016 Financial Results 54

Feb 29, 2016: Juno Therapeutics Reports Fourth Quarter and 2015 Financial Results 57

Corporate Communications 60

Apr 19, 2017: Juno Therapeutics Appoints Rupert Vessey to Board of Directors 60

Apr 17, 2017: Juno Therapeutics Appoints Sunil Agarwal as President of Research and Development 61

Jan 27, 2017: Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development Operations 62

Government and Public Interest 63

May 04, 2016: Editas Medicine Achieves Milestone under its Collaboration with Juno Therapeutics 63

Product News 64

12/03/2016: Juno Therapeutics Announces Complete Response and Corresponding Early Survival Data for JCAR014 in Patients with Ibrutinib-Refractory CLL 64

09/07/2016: JCAR014 Clinical Data Published in Science Translational Medicine: Patients with Advanced Lymphoma in Remission after T-cell Therapy 65

06/04/2016: Juno Therapeutics' Defined Composition CD19 Product Candidates Demonstrate Encouraging Clinical Outcomes and Tolerability 66

05/18/2016: Juno Therapeutics to Highlights New Efficacy, Safety, and Durability data for JCAR-014 at the 2016 American Society of Clinical Oncology Annual Meeting 67

04/20/2016: Juno Therapeutics Presents Clinical Data of JTCR-016 at American Association for Cancer Research (AACR) Annual Meeting 2016 68

Clinical Trials 69

Dec 06, 2016: Juno Therapeutics Presents data on investigational CAR T cell product candidate JCAR-014 at 58th American Society of Hematology 69

Nov 23, 2016: Juno Therapeutics Places JCAR015 Phase II ROCKET Trial on Clinical Hold 70

Jul 12, 2016: Juno Therapeutics to Resume JCAR015 Phase II ROCKET Trial 71

Jul 07, 2016: Juno Therapeutics Reports Clinical Hold on the JCAR015 Phase II ROCKET Trial 72

Jun 04, 2016: Juno Therapeutics' Investigational CAR T Cell Product Candidate JCAR015 Shows High Response Rates in Adults with B-cell ALL 73

May 18, 2016: Juno Therapeutics to Highlight JCAR-015 at the 2016 American Society of Clinical Oncology Annual Meeting 74

Apr 14, 2016: Juno Therapeutics Announces First clinical data for the WT-1 TCR product candidate, JTCR016 at the American Association for Cancer Research Annual Meeting 75

Apr 14, 2016: Juno Therapeutics Announces Presentation on JCAR024 at the American Association for Cancer Research Annual Meeting 76

Appendix 77

Methodology 77

About GlobalData 77

Contact Us 77

Disclaimer 77

List of Figures

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Juno Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Juno Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Juno Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Juno Therapeutics Raises USD134 Million in Series B Financing 13

Juno Therapeutics Raises US$31 Million In Extended Series A Financing 13

Juno Therapeutics Raises US$145 Million In Series A Financing 14

AbVitro Raises US$0.75 Million In Venture Financing 16

AbVitro Secures USD5.5 Million in Venture Funding from Sante Ventures 16

X-BODY Raises Additional US$0.6 Million In Venture Financing 17

Seattle Children's Hospital to Enter into Agreement with Juno Therapeutics 17

Juno Therapeutics Forms Joint Venture with WuXi AppTec 18

Juno Therapeutics and Fred Hutchinson Cancer Research Center Enter into Joint Venture 19

Celgene Exercises Option Agreement with Juno Therapeutics 20

Juno Therapeutics Enters into Research Agreement with Editas Medicine 21

MedImmune Enters into Agreement with Juno Therapeutics 22

Juno Therapeutics Enters into Research Agreement with FHCRC 22

X-Body BioSciences Enters Into Co-Development Agreement With Jiangsu Hengrui Medicine For AMD 23

X-BODY Enters Into Research Agreement With Tanabe Research Labs 24

Mercator Therapeutics Enters Into Co-Development Agreement With X-BODY BioSciences 25

Juno Therapeutics Enters into Licensing Agreement with MSK and Eureka Therapeutics 26

Celgene Enters into Licensing Agreement with Juno Therapeutics 27

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center and Eureka Therapeutics 28

Juno Therapeutics Enters into Research Collaboration and Licensing Agreement with Fate Therapeutics 29

Juno Therapeutics Amends its Licensing Agreement with Opus Bioc 30

Vernalis Enters into Licensing Agreement with RedoxTherapies 31

Juno Therapeutics Enters into Licensing Agreement with Memorial Sloan Kettering Cancer Center 32

Juno Therapeutics Enters into Licensing Agreement with FHCRC 33

Juno Therapeutics Raises USD304 Million in IPO 34

Roche Acquires PETE Technology from AbVitro 35

Juno Therapeutics Acquires RedoxTherapies 36

Juno Therapeutics Acquires AbVitro 37

Juno Therapeutics Acquires X-BODY 38

AstraZeneca May Acquire Juno Therapeutics 39

Juno Therapeutics Acquires Remaining 95% Stake in Stage Cell Therapeutics 39

Juno Therapeutics Acquires ZetaRx BioSciences 40

Juno Therapeutics Inc, Key Competitors 42

Juno Therapeutics Inc, Key Employees 43

Juno Therapeutics Inc, Other Locations 44

Juno Therapeutics Inc, Subsidiaries 44

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Juno Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16020
Site License
USD 500 INR 32040
Corporate User License
USD 750 INR 48060

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com